Literature DB >> 28149054

Molecular docking based screening of compounds against VP40 from Ebola virus.

Hanaa M Alam El-Din1, Samah A Loutfy1, Nasra Fathy1, Mostafa H Elberry1, Ahmed M Mayla1, Sara Kassem2, Asif Naqvi3.   

Abstract

Ebola virus causes severe and often fatal hemorrhagic fevers in humans. The 2014 Ebola epidemic affected multiple countries. The virus matrix protein (VP40) plays a central role in virus assembly and budding. Since there is no FDA-approved vaccine or medicine against Ebola viral infection, discovering new compounds with different binding patterns against it is required. Therefore, we aim to identify small molecules that target the Arg 134 RNA binding and active site of VP40 protein. 1800 molecules were retrieved from PubChem compound database based on Structure Similarity and Conformers of pyrimidine-2, 4-dione. Molecular docking approach using Lamarckian Genetic Algorithm was carried out to find the potent inhibitors for VP40 based on calculated ligand-protein pairwise interaction energies. The grid maps representing the protein were calculated using auto grid and grid size was set to 60*60*60 points with grid spacing of 0.375 Ǻ. Ten independent docking runs were carried out for each ligand and results were clustered according to the 1.0 Ǻ RMSD criteria. The post-docking analysis showed that binding energies ranged from -8.87 to 0.6 Kcal/mol. We report 7 molecules, which showed promising ADMET results, LD-50, as well as H-bond interaction in the binding pocket. The small molecules discovered could act as potential inhibitors for VP40 and could interfere with virus assembly and budding process.

Entities:  

Keywords:  Ebola VP40; Lamarcking GA; anti-PV40 agents; molecular docking; proteomics; virtual screening

Year:  2016        PMID: 28149054      PMCID: PMC5267963          DOI: 10.6026/97320630012192

Source DB:  PubMed          Journal:  Bioinformation        ISSN: 0973-2063


  10 in total

1.  SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Authors:  N Guex; M C Peitsch
Journal:  Electrophoresis       Date:  1997-12       Impact factor: 3.535

2.  Structural rearrangement of ebola virus VP40 begets multiple functions in the virus life cycle.

Authors:  Zachary A Bornholdt; Takeshi Noda; Dafna M Abelson; Peter Halfmann; Malcolm R Wood; Yoshihiro Kawaoka; Erica Ollmann Saphire
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

3.  A new Ebola virus nonstructural glycoprotein expressed through RNA editing.

Authors:  Masfique Mehedi; Darryl Falzarano; Jochen Seebach; Xiaojie Hu; Michael S Carpenter; Hans-Joachim Schnittler; Heinz Feldmann
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

4.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

5.  Molecular docking based screening of predicted potential inhibitors for VP40 from Ebola virus.

Authors:  Danya Abazari; Mehrad Moghtadaei; Ali Behvarmanesh; Bahareh Ghannadi; Monireh Aghaei; Mahboobeh Behruznia; Garshasb Rigi
Journal:  Bioinformation       Date:  2015-05-28

6.  The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties.

Authors:  F Xavier Gomis-Rüth; Andréa Dessen; Joanna Timmins; Andreas Bracher; Larissa Kolesnikowa; Stephan Becker; Hans Dieter Klenk; Winfried Weissenhorn
Journal:  Structure       Date:  2003-04       Impact factor: 5.006

Review 7.  Development of Small-Molecule Antivirals for Ebola.

Authors:  Zlatko Janeba
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

8.  High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus.

Authors:  Thangaraju Tamilvanan; Waheeta Hopper
Journal:  Bioinformation       Date:  2013-03-19

9.  ProTox: a web server for the in silico prediction of rodent oral toxicity.

Authors:  Malgorzata N Drwal; Priyanka Banerjee; Mathias Dunkel; Martin R Wettig; Robert Preissner
Journal:  Nucleic Acids Res       Date:  2014-05-16       Impact factor: 16.971

10.  Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus.

Authors:  V Karthick; N Nagasundaram; C George Priya Doss; Chiranjib Chakraborty; R Siva; Aiping Lu; Ge Zhang; Hailong Zhu
Journal:  Infect Dis Poverty       Date:  2016-02-17       Impact factor: 4.520

  10 in total
  4 in total

Review 1.  A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.

Authors:  James Schuler; Matthew L Hudson; Diane Schwartz; Ram Samudrala
Journal:  Molecules       Date:  2017-10-20       Impact factor: 4.411

Review 2.  Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Sandip Chakraborty; Ashok Munjal; Shyma K Latheef; Deepak Kumar; Muthannan Andavar Ramakrishnan; Yashpal Singh Malik; Rajendra Singh; Satya Veer Singh Malik; Raj Kumar Singh; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

3.  Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors.

Authors:  Hasanain Abdulhameed Odhar; Ali Mahmood Rayshan; Salam Waheed Ahjel; Alaa Abduljabbar Hashim; Ali A Mohammed Ali Albeer
Journal:  Bioinformation       Date:  2019-10-08

Review 4.  Therapeutic Strategies against Ebola Virus Infection.

Authors:  Ching-Hsuan Liu; Yee-Tung Hu; Shu Hui Wong; Liang-Tzung Lin
Journal:  Viruses       Date:  2022-03-11       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.